Skip to main content
. 2019 Feb 8;98(6):e14400. doi: 10.1097/MD.0000000000014400

Figure 3.

Figure 3

The relative benefits of statins, PCSK9 inhibitors, ezetimibe, and placebo against cardiovascular events, all-cause mortality and cardiovascular mortality in patients with hypercholesterolemia. Data are presented with odds ratios and 95% confidence intervals. PCSK9 = proprotein convertase subtilisin-kexin type 9 serine protease.